<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109914</url>
  </required_header>
  <id_info>
    <org_study_id>MICH P10.011</org_study_id>
    <nct_id>NCT01109914</nct_id>
  </id_info>
  <brief_title>Mucosal Response in Immunocompromised Host</brief_title>
  <acronym>MICH</acronym>
  <official_title>Immune Response After Inactivated Oral Cholera Vaccine (Dukoral) in Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crucell B.V., Leiden, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to verify whether vaccination with Dukoral® (SBL Vaccines) induces
      an immune response in renal transplant recipients on prednisolone in combination with either
      a calcineurin inhibitor CNI) or mycophenolate mofetil (MMF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      LT-ETEC is the most common cause of travelers' diarrhoea. Dukoral® (SBL Vaccines) reduces the
      severity and duration of LT-ETEC induced diarrhea. Dehydration due to diarrhea poses a risk
      to the health of renal transplant recipients. Therefore Dukoral may benefit this group of
      travelers.

      AIM OF THIS STUDY:

      Primary objective: To verify whether vaccination with Dukoral® (SBL Vaccines) induces an
      immune response in renal transplant recipients on prednisolone in combination with either a
      calcineurin inhibitor (cyclosporine or tacrolimus) or mycophenolate mofetil.

      Secondary objective: To evaluate to what extent, the immune response differs, depending on
      the use of different classes of immunosuppressive drugs (CNI or MMF).

      STUDY DESIGN:

      Single center interventional study.

      Population: The population base of the study consists of adult renal transplant recipients
      who received their transplant at our medical center. The control population consists of the
      healthy partners and siblings of the renal transplant recipients. We intend to include 10
      healthy volunteers and 60 renal transplant recipients (20 on prednisolone and a CNI and 20 on
      prednisolone and MMF).

      Intervention: Dukoral® (SBL Vaccines) will be administered orally at baseline (day 0) and at
      day 14.

      Laboratory analysis: Serum CTB antibody (ELISA), Vibriocidal assay. The analysis is performed
      at Crucell.

      Statistical analysis: No formal sample-size calculation was performed. The crude outcome
      estimates will be adjusted for variables that may influence the outcome (age, time after
      transplantation, past treatment for transplant rejection, current renal function, cumulative
      prednisolone dose, serum concentration (i.e. area under the curve) of CNI and MMF.

      Note: the study intended to also recruit a study arm consisting of patients on a mTORi.
      Recruitment for this study arm was unsuccesful due to the scarcity of elligible patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage seroconversion among all renal transplant recipients.</measure>
    <time_frame>day 20-22</time_frame>
    <description>≥3-fold rise in serum anti-CTB antibodies or ≥4-fold rise in serum vibriocidal antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group differences in geometric mean antibody titers after vaccination</measure>
    <time_frame>day 20-22</time_frame>
    <description>post-vaccination anti-rCTB titers, measured by Enzyme Immuno Assay (EIA); post-vaccination serum vibriocidal antibodies, measured in vibriocidal assay.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>Renal transplant recipients (MMF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.
Intervention: vaccination with Dukoral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal transplant recipients (CNI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.
Intervention: vaccination with Dukoral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).
Intervention: vaccination with Dukoral</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dukoral</intervention_name>
    <description>Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:
Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria* −Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)</description>
    <arm_group_label>Renal transplant recipients (MMF)</arm_group_label>
    <arm_group_label>Renal transplant recipients (CNI)</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        HEALTHY VOLUNTEERS

        Inclusion criteria:

          -  Above 18 years of age

          -  Informed consent

        Exclusion Criteria:

          -  History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture,
             Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and
             immunodeficiency disorders like IgA deficiency)

          -  Chronic infection

          -  Past vaccination with Dukoral or another cholera or ETEC vaccine

          -  History of infection with Vibrio cholerae

          -  Episode of diarrhoea in the 6 months prior to inclusion

          -  Allergy to vaccine-specific components

          -  History of a severe allergic reaction to any vaccine

          -  Treatment with blood products in the 3 months prior to inclusion

          -  Current pregnancy or breastfeeding

          -  Premenopausal women not willing to use contraceptives during the first 60 days after
             vaccination

          -  Use of any immunosuppressive drug

        RENAL TRANSPLANT RECIPIENTS

        Inclusion Criteria:

          -  Above 18 years of age

          -  Creatinin clearance ≥ 40 ml/min measured in the 6 months prior to inclusion

          -  Stable renal function for 1 year prior to inclusion

          -  Stable immunosuppressive regimen of a CNI, MMF or mTORi combined with prednisolone for
             at least 3 months prior to inclusion

          -  Informed Consent

        Exclusion Criteria:

          -  History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture,
             Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and
             immunodeficiency disorders like IgA deficiency)

          -  Chronic infection

          -  Treatment for rejection of the transplant in the past 1 year prior to inclusion

          -  Past vaccination with Dukoral or another cholera or ETEC vaccine

          -  History of infection with Vibrio cholerae

          -  Episode of diarrhoea in the 6 months prior to inclusion

          -  Allergy to vaccine-specific components

          -  History of a severe allergic reaction to any vaccine

          -  Treatment with blood products in the 3 months prior to inclusion

          -  Current pregnancy or breastfeeding

          -  Premenopausal women not willing to use contraceptives during the first 60 days after
             vaccination

          -  Use of an immunosuppressive drug other than CNI, MMF, mTORi or prednisolone at the the
             time of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo G Visser, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darius Soonawala, MD</last_name>
    <role>Study Director</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>O W Bredewold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J W de Fijter, Prof PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjolein AC Uijlings</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emile FF Jonker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden Univeristy Medical Centre</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Darius Soonawala</investigator_full_name>
    <investigator_title>Drs</investigator_title>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>ETEC</keyword>
  <keyword>Dukoral</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Immunity, Humoral</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

